Inactive Instrument
Biosyent Inc. Stock Toronto S.E.
Stocks
RX
CA0906901081
Pharmaceuticals
OTC Markets Traded| Market Cap | 189M 133M 118M 110M 100M 12.76B 191M 1.33B 516M 6.52B 498M 487M 20.93B | P/E 2026 * |
16.7x | P/E 2027 * | 15.6x |
|---|---|---|---|---|---|
| Enterprise Value | 189M 133M 118M 110M 100M 12.76B 191M 1.33B 516M 6.52B 498M 487M 20.93B | EV / Sales 2026 * |
2.58x | EV / Sales 2027 * | 2.27x |
| Free-Float |
64.08% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Biosyent Inc.
| 1 day | +0.37% |
| Manager | Title | Age | Since |
|---|---|---|---|
René Goehrum
CEO | Chief Executive Officer | 66 | 1999-04-30 |
Robert March
DFI | Director of Finance/CFO | - | 2018-09-09 |
Navid Ashrafi
CTO | Chief Tech/Sci/R&D Officer | - | 2015-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
René Goehrum
CHM | Chairman | 66 | 1999-05-31 |
Peter Lockhard
BRD | Director/Board Member | 62 | 2002-05-31 |
Stephen Wilton
BRD | Director/Board Member | 65 | 2014-01-15 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.37% | +3.88% | - | - | 133M | |
| -0.61% | -3.43% | +36.07% | +115.04% | 1,019B | |
| -1.02% | -5.60% | +35.72% | +64.63% | 617B | |
| +1.11% | -0.58% | +12.36% | +77.95% | 464B | |
| +0.34% | -3.01% | +61.79% | +41.24% | 356B | |
| -0.95% | -4.05% | +20.54% | +41.71% | 333B | |
| -1.46% | -2.89% | +10.57% | +32.81% | 267B | |
| -1.35% | -5.43% | -6.17% | +8.98% | 244B | |
| -1.04% | -2.79% | +35.30% | +51.84% | 218B | |
| -1.87% | -4.10% | +28.44% | +93.66% | 179B | |
| Average | -0.65% | -3.54% | +26.07% | +58.65% | 410.8B | |
| Weighted average by Cap. | -0.60% | -3.54% | +29.07% | +70.57% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 73.2M 51.35M 45.62M 42.58M 38.81M 4.94B 73.88M 515M 200M 2.52B 193M 189M 8.1B | 83.2M 58.36M 51.86M 48.4M 44.11M 5.61B 83.97M 586M 227M 2.87B 219M 214M 9.21B |
| Net income | - | - |
| Net Debt | - | - |
Employees
-
Sector
Pharmaceuticals
